#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Early diagnosis and treatment of human malaria reduces disease , prevents deaths , and contributes to reduced transmission .
2-1	16-21	Early	event[2]|abstract[3]	new[2]|new[3]	coref|coref	5-13[38_2]|13-15[149_3]
2-2	22-31	diagnosis	event[2]|abstract[3]	new[2]|new[3]	_	_
2-3	32-35	and	abstract[3]	new[3]	_	_
2-4	36-45	treatment	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-5	46-48	of	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-6	49-54	human	abstract[3]|abstract[4]|abstract[5]	new[3]|new[4]|new[5]	coref	3-6[0_5]
2-7	55-62	malaria	abstract[3]|abstract[4]|abstract[5]	new[3]|new[4]|new[5]	_	_
2-8	63-70	reduces	_	_	_	_
2-9	71-78	disease	abstract	new	coref	10-5
2-10	79-80	,	_	_	_	_
2-11	81-89	prevents	_	_	_	_
2-12	90-96	deaths	event	new	_	_
2-13	97-98	,	_	_	_	_
2-14	99-102	and	_	_	_	_
2-15	103-114	contributes	_	_	_	_
2-16	115-117	to	_	_	_	_
2-17	118-125	reduced	event[8]	new[8]	coref	7-23[87_8]
2-18	126-138	transmission	event[8]	new[8]	_	_
2-19	139-140	.	_	_	_	_

#Text=Detection of antibody response against malaria antigens is often done through Enzyme-Linked Immunosorbent Assay ( ELISA ) ; many of these diagnostic assays are designed with a single antigen or with recombinant antigens of different stages of the parasites ( tissue infection or blood ) , where merozoite surface proteins can be detected , and have demonstrated good sensitivity and specificity .
3-1	141-150	Detection	abstract[9]	new[9]	_	_
3-2	151-153	of	abstract[9]	new[9]	_	_
3-3	154-162	antibody	abstract[9]|substance|abstract[11]	new[9]|new|new[11]	coref	5-27
3-4	163-171	response	abstract[9]|abstract[11]	new[9]|new[11]	_	_
3-5	172-179	against	abstract[9]|abstract[11]	new[9]|new[11]	_	_
3-6	180-187	malaria	abstract[9]|abstract[11]|abstract|substance[13]	new[9]|new[11]|giv|new[13]	coref|coref	3-32[20_13]|5-16
3-7	188-196	antigens	abstract[9]|abstract[11]|substance[13]	new[9]|new[11]|new[13]	_	_
3-8	197-199	is	_	_	_	_
3-9	200-205	often	_	_	_	_
3-10	206-210	done	_	_	_	_
3-11	211-218	through	_	_	_	_
3-12	219-232	Enzyme-Linked	abstract|abstract[15]|abstract[16]	new|new[15]|new[16]	appos	3-16[0_16]
3-13	233-246	Immunosorbent	abstract[15]|abstract[16]	new[15]|new[16]	_	_
3-14	247-252	Assay	abstract[16]	new[16]	_	_
3-15	253-254	(	_	_	_	_
3-16	255-260	ELISA	abstract	giv	coref	5-8
3-17	261-262	)	_	_	_	_
3-18	263-264	;	_	_	_	_
3-19	265-269	many	_	_	_	_
3-20	270-272	of	_	_	_	_
3-21	273-278	these	abstract[18]	new[18]	_	_
3-22	279-289	diagnostic	abstract[18]	new[18]	_	_
3-23	290-296	assays	abstract[18]	new[18]	_	_
3-24	297-300	are	_	_	_	_
3-25	301-309	designed	_	_	_	_
3-26	310-314	with	_	_	_	_
3-27	315-316	a	substance[19]	new[19]	_	_
3-28	317-323	single	substance[19]	new[19]	_	_
3-29	324-331	antigen	substance[19]	new[19]	_	_
3-30	332-334	or	_	_	_	_
3-31	335-339	with	_	_	_	_
3-32	340-351	recombinant	substance[20]	giv[20]	coref	6-5[68_20]
3-33	352-360	antigens	substance[20]	giv[20]	_	_
3-34	361-363	of	substance[20]	giv[20]	_	_
3-35	364-373	different	substance[20]|abstract[21]	giv[20]|new[21]	_	_
3-36	374-380	stages	substance[20]|abstract[21]	giv[20]|new[21]	_	_
3-37	381-383	of	substance[20]|abstract[21]	giv[20]|new[21]	_	_
3-38	384-387	the	substance[20]|abstract[21]|animal[22]	giv[20]|new[21]|new[22]	coref	5-85[64_22]
3-39	388-397	parasites	substance[20]|abstract[21]|animal[22]	giv[20]|new[21]|new[22]	_	_
3-40	398-399	(	substance[20]	giv[20]	_	_
3-41	400-406	tissue	substance[20]|object	giv[20]|new	_	_
3-42	407-416	infection	substance[20]	giv[20]	_	_
3-43	417-419	or	substance[20]	giv[20]	_	_
3-44	420-425	blood	substance[20]	giv[20]	_	_
3-45	426-427	)	substance[20]	giv[20]	_	_
3-46	428-429	,	substance[20]	giv[20]	_	_
3-47	430-435	where	substance[20]	giv[20]	_	_
3-48	436-445	merozoite	substance[20]|animal|substance[26]	giv[20]|new|new[26]	_	_
3-49	446-453	surface	substance[20]|place|substance[26]	giv[20]|new|new[26]	_	_
3-50	454-462	proteins	substance[20]|substance[26]	giv[20]|new[26]	_	_
3-51	463-466	can	substance[20]	giv[20]	_	_
3-52	467-469	be	substance[20]	giv[20]	_	_
3-53	470-478	detected	substance[20]	giv[20]	_	_
3-54	479-480	,	substance[20]	giv[20]	_	_
3-55	481-484	and	substance[20]	giv[20]	_	_
3-56	485-489	have	substance[20]	giv[20]	_	_
3-57	490-502	demonstrated	substance[20]	giv[20]	_	_
3-58	503-507	good	substance[20]|abstract[27]	giv[20]|new[27]	_	_
3-59	508-519	sensitivity	substance[20]|abstract[27]	giv[20]|new[27]	_	_
3-60	520-523	and	substance[20]	giv[20]	_	_
3-61	524-535	specificity	substance[20]|abstract	giv[20]|new	_	_
3-62	536-537	.	_	_	_	_

#Text=However , many individuals cannot be easily diagnosed due to the low levels of antibodies present in their blood .
4-1	538-545	However	_	_	_	_
4-2	546-547	,	_	_	_	_
4-3	548-552	many	person[29]	new[29]	ana	4-18[0_29]
4-4	553-564	individuals	person[29]	new[29]	_	_
4-5	565-571	cannot	_	_	_	_
4-6	572-574	be	_	_	_	_
4-7	575-581	easily	_	_	_	_
4-8	582-591	diagnosed	_	_	_	_
4-9	592-595	due	_	_	_	_
4-10	596-598	to	_	_	_	_
4-11	599-602	the	abstract[30]	new[30]	_	_
4-12	603-606	low	abstract[30]	new[30]	_	_
4-13	607-613	levels	abstract[30]	new[30]	_	_
4-14	614-616	of	abstract[30]	new[30]	_	_
4-15	617-627	antibodies	abstract[30]|substance[31]	new[30]|new[31]	coref	6-3[66_31]
4-16	628-635	present	abstract[30]|substance[31]	new[30]|new[31]	_	_
4-17	636-638	in	_	_	_	_
4-18	639-644	their	person|substance[33]	giv|new[33]	coref	5-31
4-19	645-650	blood	substance[33]	new[33]	_	_
4-20	651-652	.	_	_	_	_

#Text=In this context , the use of ELISA as a tool for laboratory diagnosis of malaria has some limitations , namely : ( i ) low antibody titres presented by individuals in the acute phase of infection ; ( ii ) many Plasmodium sp. are involved in human malaria ; ( iii ) different evolutionary forms of Plasmodium spp. during infection and life cycle ; and ( iv ) different resistance and susceptibility profiles during infection , and consequently in the immunity profile against malaria parasites .
5-1	653-655	In	_	_	_	_
5-2	656-660	this	abstract[34]	new[34]	_	_
5-3	661-668	context	abstract[34]	new[34]	_	_
5-4	669-670	,	_	_	_	_
5-5	671-674	the	abstract[35]	new[35]	coref	7-17[83_35]
5-6	675-678	use	abstract[35]	new[35]	_	_
5-7	679-681	of	abstract[35]	new[35]	_	_
5-8	682-687	ELISA	abstract[35]|abstract	new[35]|giv	_	_
5-9	688-690	as	abstract[35]	new[35]	_	_
5-10	691-692	a	abstract[35]|abstract[37]	new[35]|new[37]	_	_
5-11	693-697	tool	abstract[35]|abstract[37]	new[35]|new[37]	_	_
5-12	698-701	for	abstract[35]|abstract[37]	new[35]|new[37]	_	_
5-13	702-712	laboratory	abstract[35]|abstract[37]|event[38]	new[35]|new[37]|giv[38]	_	_
5-14	713-722	diagnosis	abstract[35]|abstract[37]|event[38]	new[35]|new[37]|giv[38]	_	_
5-15	723-725	of	abstract[35]|abstract[37]|event[38]	new[35]|new[37]|giv[38]	_	_
5-16	726-733	malaria	abstract[35]|abstract[37]|event[38]|abstract	new[35]|new[37]|giv[38]|giv	coref	5-48[48_0]
5-17	734-737	has	_	_	_	_
5-18	738-742	some	abstract[40]	new[40]	appos	5-21[42_40]
5-19	743-754	limitations	abstract[40]	new[40]	_	_
5-20	755-756	,	_	_	_	_
5-21	757-763	namely	abstract[42]	giv[42]	appos	5-54[49_42]
5-22	764-765	:	abstract[42]	giv[42]	_	_
5-23	766-767	(	abstract[42]	giv[42]	_	_
5-24	768-769	i	abstract[42]	giv[42]	_	_
5-25	770-771	)	abstract[42]	giv[42]	_	_
5-26	772-775	low	abstract[42]	giv[42]	_	_
5-27	776-784	antibody	substance|abstract[42]	giv|giv[42]	_	_
5-28	785-791	titres	abstract[42]	giv[42]	_	_
5-29	792-801	presented	abstract[42]	giv[42]	_	_
5-30	802-804	by	abstract[42]	giv[42]	_	_
5-31	805-816	individuals	abstract[42]|person	giv[42]|giv	_	_
5-32	817-819	in	abstract[42]	giv[42]	_	_
5-33	820-823	the	abstract[42]|abstract[44]	giv[42]|new[44]	_	_
5-34	824-829	acute	abstract[42]|abstract[44]	giv[42]|new[44]	_	_
5-35	830-835	phase	abstract[42]|abstract[44]	giv[42]|new[44]	_	_
5-36	836-838	of	abstract[42]|abstract[44]	giv[42]|new[44]	_	_
5-37	839-848	infection	abstract[42]|abstract[44]|event	giv[42]|new[44]|new	coref	5-61
5-38	849-850	;	_	_	_	_
5-39	851-852	(	_	_	_	_
5-40	853-855	ii	_	_	_	_
5-41	856-857	)	_	_	_	_
5-42	858-862	many	substance[46]	new[46]	coref	5-58[0_46]
5-43	863-873	Plasmodium	substance[46]	new[46]	_	_
5-44	874-877	sp.	abstract	new	coref	12-27[138_0]
5-45	878-881	are	_	_	_	_
5-46	882-890	involved	_	_	_	_
5-47	891-893	in	_	_	_	_
5-48	894-899	human	abstract[48]	giv[48]	coref	5-85[0_48]
5-49	900-907	malaria	abstract[48]	giv[48]	_	_
5-50	908-909	;	_	_	_	_
5-51	910-911	(	_	_	_	_
5-52	912-915	iii	_	_	_	_
5-53	916-917	)	_	_	_	_
5-54	918-927	different	abstract[49]	giv[49]	appos	5-70[58_49]
5-55	928-940	evolutionary	abstract[49]	giv[49]	_	_
5-56	941-946	forms	abstract[49]	giv[49]	_	_
5-57	947-949	of	abstract[49]	giv[49]	_	_
5-58	950-960	Plasmodium	abstract[49]|substance|time[51]	giv[49]|giv|new[51]	coref	12-27
5-59	961-965	spp.	abstract[49]|time[51]	giv[49]|new[51]	_	_
5-60	966-972	during	abstract[49]	giv[49]	_	_
5-61	973-982	infection	abstract[49]|event|event[53]	giv[49]|giv|new[53]	coref|ana	5-76|6-16[0_53]
5-62	983-986	and	abstract[49]|event[53]	giv[49]|new[53]	_	_
5-63	987-991	life	abstract[49]|event[53]|abstract|abstract[55]	giv[49]|new[53]|new|new[55]	_	_
5-64	992-997	cycle	abstract[49]|event[53]|abstract[55]	giv[49]|new[53]|new[55]	_	_
5-65	998-999	;	_	_	_	_
5-66	1000-1003	and	_	_	_	_
5-67	1004-1005	(	_	_	_	_
5-68	1006-1008	iv	_	_	_	_
5-69	1009-1010	)	_	_	_	_
5-70	1011-1020	different	abstract[56]|abstract[58]|abstract[59]	new[56]|giv[58]|giv[59]	appos|appos	5-70[59_58]|5-79[62_59]
5-71	1021-1031	resistance	abstract[56]|abstract[58]|abstract[59]	new[56]|giv[58]|giv[59]	_	_
5-72	1032-1035	and	abstract[58]|abstract[59]	giv[58]|giv[59]	_	_
5-73	1036-1050	susceptibility	abstract|abstract[58]|abstract[59]	new|giv[58]|giv[59]	_	_
5-74	1051-1059	profiles	abstract[58]|abstract[59]	giv[58]|giv[59]	_	_
5-75	1060-1066	during	abstract[58]|abstract[59]	giv[58]|giv[59]	_	_
5-76	1067-1076	infection	abstract[58]|abstract[59]|event	giv[58]|giv[59]|giv	_	_
5-77	1077-1078	,	abstract[59]	giv[59]	_	_
5-78	1079-1082	and	abstract[59]	giv[59]	_	_
5-79	1083-1095	consequently	abstract[59]|abstract[62]	giv[59]|giv[62]	_	_
5-80	1096-1098	in	abstract[59]|abstract[62]	giv[59]|giv[62]	_	_
5-81	1099-1102	the	abstract[59]|abstract[62]	giv[59]|giv[62]	_	_
5-82	1103-1111	immunity	abstract[59]|abstract|abstract[62]	giv[59]|new|giv[62]	_	_
5-83	1112-1119	profile	abstract[59]|abstract[62]	giv[59]|giv[62]	_	_
5-84	1120-1127	against	abstract[59]|abstract[62]	giv[59]|giv[62]	_	_
5-85	1128-1135	malaria	abstract[59]|abstract[62]|abstract|animal[64]	giv[59]|giv[62]|giv|giv[64]	coref|coref	6-8|11-10[124_64]
5-86	1136-1145	parasites	abstract[59]|abstract[62]|animal[64]	giv[59]|giv[62]|giv[64]	_	_
5-87	1146-1147	.	_	_	_	_

#Text=Associations among antibodies against parasite antigens and malaria risk areas are not always consistent ; some may depend on parasite antigens and other considerations may be due to the endemic areas of malaria .
6-1	1148-1160	Associations	abstract[65]	new[65]	_	_
6-2	1161-1166	among	abstract[65]	new[65]	_	_
6-3	1167-1177	antibodies	abstract[65]|substance[66]	new[65]|giv[66]	coref	7-9[81_66]
6-4	1178-1185	against	abstract[65]|substance[66]	new[65]|giv[66]	_	_
6-5	1186-1194	parasite	abstract[65]|substance[66]|animal|substance[68]|substance[69]	new[65]|giv[66]|new|giv[68]|giv[69]	coref|coref|coref	6-5[69_68]|6-20|6-20[75_69]
6-6	1195-1203	antigens	abstract[65]|substance[66]|substance[68]|substance[69]	new[65]|giv[66]|giv[68]|giv[69]	_	_
6-7	1204-1207	and	abstract[65]|substance[66]|substance[69]	new[65]|giv[66]|giv[69]	_	_
6-8	1208-1215	malaria	abstract[65]|substance[66]|substance[69]|abstract|place[72]	new[65]|giv[66]|giv[69]|giv|new[72]	coref|coref	6-29[77_72]|6-33
6-9	1216-1220	risk	abstract[65]|substance[66]|substance[69]|abstract|place[72]	new[65]|giv[66]|giv[69]|new|new[72]	coref	9-19[101_0]
6-10	1221-1226	areas	abstract[65]|substance[66]|substance[69]|place[72]	new[65]|giv[66]|giv[69]|new[72]	_	_
6-11	1227-1230	are	_	_	_	_
6-12	1231-1234	not	_	_	_	_
6-13	1235-1241	always	_	_	_	_
6-14	1242-1252	consistent	_	_	_	_
6-15	1253-1254	;	_	_	_	_
6-16	1255-1259	some	event	giv	_	_
6-17	1260-1263	may	_	_	_	_
6-18	1264-1270	depend	_	_	_	_
6-19	1271-1273	on	_	_	_	_
6-20	1274-1282	parasite	animal|substance[75]	giv|giv[75]	coref	7-11[0_75]
6-21	1283-1291	antigens	substance[75]	giv[75]	_	_
6-22	1292-1295	and	_	_	_	_
6-23	1296-1301	other	abstract[76]	new[76]	_	_
6-24	1302-1316	considerations	abstract[76]	new[76]	_	_
6-25	1317-1320	may	_	_	_	_
6-26	1321-1323	be	_	_	_	_
6-27	1324-1327	due	_	_	_	_
6-28	1328-1330	to	_	_	_	_
6-29	1331-1334	the	place[77]	giv[77]	_	_
6-30	1335-1342	endemic	place[77]	giv[77]	_	_
6-31	1343-1348	areas	place[77]	giv[77]	_	_
6-32	1349-1351	of	place[77]	giv[77]	_	_
6-33	1352-1359	malaria	place[77]|abstract	giv[77]|giv	ana	7-1
6-34	1360-1361	.	_	_	_	_

#Text=It should be considered that single responses of antibodies against antigens might be inadequate to for use as biomarkers and indicators of malaria transmission intensity .
7-1	1362-1364	It	abstract	giv	coref	7-23
7-2	1365-1371	should	_	_	_	_
7-3	1372-1374	be	_	_	_	_
7-4	1375-1385	considered	_	_	_	_
7-5	1386-1390	that	_	_	_	_
7-6	1391-1397	single	abstract[80]	new[80]	_	_
7-7	1398-1407	responses	abstract[80]	new[80]	_	_
7-8	1408-1410	of	abstract[80]	new[80]	_	_
7-9	1411-1421	antibodies	abstract[80]|substance[81]	new[80]|giv[81]	coref	12-15[133_81]
7-10	1422-1429	against	abstract[80]|substance[81]	new[80]|giv[81]	_	_
7-11	1430-1438	antigens	abstract[80]|substance[81]|substance	new[80]|giv[81]|giv	coref	12-24[136_0]
7-12	1439-1444	might	_	_	_	_
7-13	1445-1447	be	_	_	_	_
7-14	1448-1458	inadequate	_	_	_	_
7-15	1459-1461	to	_	_	_	_
7-16	1462-1465	for	_	_	_	_
7-17	1466-1469	use	abstract[83]	giv[83]	_	_
7-18	1470-1472	as	abstract[83]	giv[83]	_	_
7-19	1473-1483	biomarkers	abstract[83]|abstract	giv[83]|new	coref	8-6[90_0]
7-20	1484-1487	and	abstract[83]	giv[83]	_	_
7-21	1488-1498	indicators	abstract[83]|abstract[85]	giv[83]|new[85]	_	_
7-22	1499-1501	of	abstract[83]|abstract[85]	giv[83]|new[85]	_	_
7-23	1502-1509	malaria	abstract[83]|abstract[85]|abstract|event[87]|abstract[88]	giv[83]|new[85]|giv|giv[87]|new[88]	coref	9-21
7-24	1510-1522	transmission	abstract[83]|abstract[85]|event[87]|abstract[88]	giv[83]|new[85]|giv[87]|new[88]	_	_
7-25	1523-1532	intensity	abstract[83]|abstract[85]|abstract[88]	giv[83]|new[85]|new[88]	_	_
7-26	1533-1534	.	_	_	_	_

#Text=Other authors have shown that new serological biomarkers can more accurately estimate the recent exposure to P. falciparum not only of a community , but also for several communities .
8-1	1535-1540	Other	person[89]	new[89]	_	_
8-2	1541-1548	authors	person[89]	new[89]	_	_
8-3	1549-1553	have	_	_	_	_
8-4	1554-1559	shown	_	_	_	_
8-5	1560-1564	that	_	_	_	_
8-6	1565-1568	new	abstract[90]	giv[90]	_	_
8-7	1569-1580	serological	abstract[90]	giv[90]	_	_
8-8	1581-1591	biomarkers	abstract[90]	giv[90]	_	_
8-9	1592-1595	can	_	_	_	_
8-10	1596-1600	more	_	_	_	_
8-11	1601-1611	accurately	_	_	_	_
8-12	1612-1620	estimate	_	_	_	_
8-13	1621-1624	the	event[91]	new[91]	_	_
8-14	1625-1631	recent	event[91]	new[91]	_	_
8-15	1632-1640	exposure	event[91]	new[91]	_	_
8-16	1641-1643	to	event[91]	new[91]	_	_
8-17	1644-1646	P.	event[91]|animal|animal[93]	new[91]|new|new[93]	coref|coref	9-23[103_0]|12-40[142_93]
8-18	1647-1657	falciparum	event[91]|animal[93]	new[91]|new[93]	_	_
8-19	1658-1661	not	_	_	_	_
8-20	1662-1666	only	organization[94]	new[94]	_	_
8-21	1667-1669	of	organization[94]	new[94]	_	_
8-22	1670-1671	a	organization[94]	new[94]	_	_
8-23	1672-1681	community	organization[94]	new[94]	_	_
8-24	1682-1683	,	_	_	_	_
8-25	1684-1687	but	_	_	_	_
8-26	1688-1692	also	_	_	_	_
8-27	1693-1696	for	_	_	_	_
8-28	1697-1704	several	organization[95]	new[95]	_	_
8-29	1705-1716	communities	organization[95]	new[95]	_	_
8-30	1717-1718	.	_	_	_	_

#Text=In 2015 , approximately 3.2 billion people — nearly half of the world ’s population — were at risk of malaria , mainly by P. falciparum .
9-1	1719-1721	In	_	_	_	_
9-2	1722-1726	2015	time	new	_	_
9-3	1727-1728	,	_	_	_	_
9-4	1729-1742	approximately	person[97]	new[97]	_	_
9-5	1743-1746	3.2	person[97]	new[97]	_	_
9-6	1747-1754	billion	person[97]	new[97]	_	_
9-7	1755-1761	people	person[97]	new[97]	_	_
9-8	1762-1763	—	_	_	_	_
9-9	1764-1770	nearly	abstract[98]	new[98]	_	_
9-10	1771-1775	half	abstract[98]	new[98]	_	_
9-11	1776-1778	of	abstract[98]	new[98]	_	_
9-12	1779-1782	the	abstract[98]|person[100]	new[98]|new[100]	_	_
9-13	1783-1788	world	abstract[98]|place[99]|person[100]	new[98]|new[99]|new[100]	_	_
9-14	1789-1791	’s	abstract[98]|place[99]|person[100]	new[98]|new[99]|new[100]	_	_
9-15	1792-1802	population	abstract[98]|person[100]	new[98]|new[100]	_	_
9-16	1803-1804	—	_	_	_	_
9-17	1805-1809	were	_	_	_	_
9-18	1810-1812	at	_	_	_	_
9-19	1813-1817	risk	abstract[101]	giv[101]	_	_
9-20	1818-1820	of	abstract[101]	giv[101]	_	_
9-21	1821-1828	malaria	abstract[101]|abstract	giv[101]|giv	coref	10-9
9-22	1829-1830	,	abstract[101]	giv[101]	_	_
9-23	1831-1837	mainly	abstract[101]|animal[103]	giv[101]|giv[103]	coref	11-1[120_103]
9-24	1838-1840	by	abstract[101]|animal[103]	giv[101]|giv[103]	_	_
9-25	1841-1843	P.	abstract[101]|animal[103]	giv[101]|giv[103]	_	_
9-26	1844-1854	falciparum	abstract[101]|animal[103]	giv[101]|giv[103]	_	_
9-27	1855-1856	.	_	_	_	_

#Text=After several decades of disease control campaigns , malaria persists as one of the most serious public health problems , not only in endemic countries , but also in non-endemic regions , where the number of cases of imported malaria via tourists and immigrants is on the rise .
10-1	1857-1862	After	_	_	_	_
10-2	1863-1870	several	time[104]	new[104]	_	_
10-3	1871-1878	decades	time[104]	new[104]	_	_
10-4	1879-1881	of	time[104]	new[104]	_	_
10-5	1882-1889	disease	time[104]|abstract|abstract[106]|event[107]	new[104]|giv|new[106]|new[107]	coref	11-29[128_0]
10-6	1890-1897	control	time[104]|abstract[106]|event[107]	new[104]|new[106]|new[107]	_	_
10-7	1898-1907	campaigns	time[104]|event[107]	new[104]|new[107]	_	_
10-8	1908-1909	,	_	_	_	_
10-9	1910-1917	malaria	abstract	giv	coref	10-39[116_0]
10-10	1918-1926	persists	_	_	_	_
10-11	1927-1929	as	_	_	_	_
10-12	1930-1933	one	plant[109]	new[109]	coref	11-4[0_109]
10-13	1934-1936	of	plant[109]	new[109]	_	_
10-14	1937-1940	the	plant[109]|abstract[111]	new[109]|new[111]	_	_
10-15	1941-1945	most	plant[109]|abstract[111]	new[109]|new[111]	_	_
10-16	1946-1953	serious	plant[109]|abstract[111]	new[109]|new[111]	_	_
10-17	1954-1960	public	plant[109]|abstract[110]|abstract[111]	new[109]|new[110]|new[111]	_	_
10-18	1961-1967	health	plant[109]|abstract[110]|abstract[111]	new[109]|new[110]|new[111]	_	_
10-19	1968-1976	problems	plant[109]|abstract[111]	new[109]|new[111]	_	_
10-20	1977-1978	,	_	_	_	_
10-21	1979-1982	not	_	_	_	_
10-22	1983-1987	only	place[112]	new[112]	_	_
10-23	1988-1990	in	place[112]	new[112]	_	_
10-24	1991-1998	endemic	place[112]	new[112]	_	_
10-25	1999-2008	countries	place[112]	new[112]	_	_
10-26	2009-2010	,	_	_	_	_
10-27	2011-2014	but	_	_	_	_
10-28	2015-2019	also	_	_	_	_
10-29	2020-2022	in	_	_	_	_
10-30	2023-2034	non-endemic	place[113]	new[113]	_	_
10-31	2035-2042	regions	place[113]	new[113]	_	_
10-32	2043-2044	,	place[113]	new[113]	_	_
10-33	2045-2050	where	place[113]	new[113]	_	_
10-34	2051-2054	the	place[113]|abstract[114]|event[119]	new[113]|new[114]|new[119]	_	_
10-35	2055-2061	number	place[113]|abstract[114]|event[119]	new[113]|new[114]|new[119]	_	_
10-36	2062-2064	of	place[113]|abstract[114]|event[119]	new[113]|new[114]|new[119]	_	_
10-37	2065-2070	cases	place[113]|abstract[114]|abstract[115]|event[119]	new[113]|new[114]|new[115]|new[119]	_	_
10-38	2071-2073	of	place[113]|abstract[114]|abstract[115]|event[119]	new[113]|new[114]|new[115]|new[119]	_	_
10-39	2074-2082	imported	place[113]|abstract[114]|abstract[115]|abstract[116]|event[119]	new[113]|new[114]|new[115]|giv[116]|new[119]	coref	11-11[0_116]
10-40	2083-2090	malaria	place[113]|abstract[114]|abstract[115]|abstract[116]|event[119]	new[113]|new[114]|new[115]|giv[116]|new[119]	_	_
10-41	2091-2094	via	place[113]|abstract[114]|abstract[115]|event[119]	new[113]|new[114]|new[115]|new[119]	_	_
10-42	2095-2103	tourists	place[113]|abstract[114]|abstract[115]|person|event[119]	new[113]|new[114]|new[115]|new|new[119]	_	_
10-43	2104-2107	and	place[113]|abstract[114]|abstract[115]|event[119]	new[113]|new[114]|new[115]|new[119]	_	_
10-44	2108-2118	immigrants	place[113]|abstract[114]|abstract[115]|person|event[119]	new[113]|new[114]|new[115]|new|new[119]	_	_
10-45	2119-2121	is	place[113]|event[119]	new[113]|new[119]	_	_
10-46	2122-2124	on	place[113]|event[119]	new[113]|new[119]	_	_
10-47	2125-2128	the	place[113]|event[119]	new[113]|new[119]	_	_
10-48	2129-2133	rise	place[113]|event[119]	new[113]|new[119]	_	_
10-49	2134-2135	.	_	_	_	_

#Text=P. falciparum is one the most lethal species of the malaria parasites that infect humans , and is responsible for the highest number of serious pathologies associated with the disease .
11-1	2136-2138	P.	animal[120]	giv[120]	coref	12-40[0_120]
11-2	2139-2149	falciparum	animal[120]	giv[120]	_	_
11-3	2150-2152	is	_	_	_	_
11-4	2153-2156	one	plant	giv	coref	11-5[122_0]
11-5	2157-2160	the	plant[122]	giv[122]	_	_
11-6	2161-2165	most	plant[122]	giv[122]	_	_
11-7	2166-2172	lethal	plant[122]	giv[122]	_	_
11-8	2173-2180	species	plant[122]	giv[122]	_	_
11-9	2181-2183	of	plant[122]	giv[122]	_	_
11-10	2184-2187	the	plant[122]|animal[124]	giv[122]|giv[124]	_	_
11-11	2188-2195	malaria	plant[122]|abstract|animal[124]	giv[122]|giv|giv[124]	coref	13-19
11-12	2196-2205	parasites	plant[122]|animal[124]	giv[122]|giv[124]	_	_
11-13	2206-2210	that	plant[122]|animal[124]	giv[122]|giv[124]	_	_
11-14	2211-2217	infect	plant[122]|animal[124]	giv[122]|giv[124]	_	_
11-15	2218-2224	humans	plant[122]|animal[124]|animal	giv[122]|giv[124]|new	_	_
11-16	2225-2226	,	_	_	_	_
11-17	2227-2230	and	_	_	_	_
11-18	2231-2233	is	_	_	_	_
11-19	2234-2245	responsible	_	_	_	_
11-20	2246-2249	for	_	_	_	_
11-21	2250-2253	the	abstract[126]	new[126]	_	_
11-22	2254-2261	highest	abstract[126]	new[126]	_	_
11-23	2262-2268	number	abstract[126]	new[126]	_	_
11-24	2269-2271	of	abstract[126]	new[126]	_	_
11-25	2272-2279	serious	abstract[126]|abstract[127]	new[126]|new[127]	_	_
11-26	2280-2291	pathologies	abstract[126]|abstract[127]	new[126]|new[127]	_	_
11-27	2292-2302	associated	abstract[126]|abstract[127]	new[126]|new[127]	_	_
11-28	2303-2307	with	abstract[126]|abstract[127]	new[126]|new[127]	_	_
11-29	2308-2311	the	abstract[126]|abstract[127]|abstract[128]	new[126]|new[127]|giv[128]	_	_
11-30	2312-2319	disease	abstract[126]|abstract[127]|abstract[128]	new[126]|new[127]|giv[128]	_	_
11-31	2320-2321	.	_	_	_	_

#Text=In this work , we performed a comparative analysis of the serological reactivity of total antimalarial antibodies obtained by a commercial ELISA using recombinant antigens from Plasmodium sp. , compared to an in-house ELISA , using crude extract of P. falciparum 3D7 .
12-1	2322-2324	In	_	_	_	_
12-2	2325-2329	this	abstract[129]	new[129]	_	_
12-3	2330-2334	work	abstract[129]	new[129]	_	_
12-4	2335-2336	,	_	_	_	_
12-5	2337-2339	we	person	acc	ana	13-3
12-6	2340-2349	performed	_	_	_	_
12-7	2350-2351	a	abstract[131]	new[131]	_	_
12-8	2352-2363	comparative	abstract[131]	new[131]	_	_
12-9	2364-2372	analysis	abstract[131]	new[131]	_	_
12-10	2373-2375	of	abstract[131]	new[131]	_	_
12-11	2376-2379	the	abstract[131]|abstract[132]	new[131]|new[132]	_	_
12-12	2380-2391	serological	abstract[131]|abstract[132]	new[131]|new[132]	_	_
12-13	2392-2402	reactivity	abstract[131]|abstract[132]	new[131]|new[132]	_	_
12-14	2403-2405	of	abstract[131]|abstract[132]	new[131]|new[132]	_	_
12-15	2406-2411	total	abstract[131]|abstract[132]|substance[133]	new[131]|new[132]|giv[133]	_	_
12-16	2412-2424	antimalarial	abstract[131]|abstract[132]|substance[133]	new[131]|new[132]|giv[133]	_	_
12-17	2425-2435	antibodies	abstract[131]|abstract[132]|substance[133]	new[131]|new[132]|giv[133]	_	_
12-18	2436-2444	obtained	abstract[131]|abstract[132]|substance[133]	new[131]|new[132]|giv[133]	_	_
12-19	2445-2447	by	abstract[131]|abstract[132]|substance[133]	new[131]|new[132]|giv[133]	_	_
12-20	2448-2449	a	abstract[131]|abstract[132]|substance[133]|person[134]	new[131]|new[132]|giv[133]|new[134]	coref	12-32[139_134]
12-21	2450-2460	commercial	abstract[131]|abstract[132]|substance[133]|person[134]	new[131]|new[132]|giv[133]|new[134]	_	_
12-22	2461-2466	ELISA	abstract[131]|abstract[132]|substance[133]|person[134]	new[131]|new[132]|giv[133]|new[134]	_	_
12-23	2467-2472	using	abstract[131]|abstract[132]|substance[133]|person[134]	new[131]|new[132]|giv[133]|new[134]	_	_
12-24	2473-2484	recombinant	abstract[131]|abstract[132]|substance[133]|person[134]|person|substance[136]	new[131]|new[132]|giv[133]|new[134]|new|giv[136]	coref	13-6[147_136]
12-25	2485-2493	antigens	abstract[131]|abstract[132]|substance[133]|person[134]|substance[136]	new[131]|new[132]|giv[133]|new[134]|giv[136]	_	_
12-26	2494-2498	from	abstract[131]|abstract[132]|substance[133]|person[134]|substance[136]	new[131]|new[132]|giv[133]|new[134]|giv[136]	_	_
12-27	2499-2509	Plasmodium	abstract[131]|abstract[132]|substance[133]|person[134]|substance[136]|substance|abstract[138]	new[131]|new[132]|giv[133]|new[134]|giv[136]|giv|giv[138]	_	_
12-28	2510-2513	sp.	abstract[131]|abstract[132]|substance[133]|person[134]|substance[136]|abstract[138]	new[131]|new[132]|giv[133]|new[134]|giv[136]|giv[138]	_	_
12-29	2514-2515	,	_	_	_	_
12-30	2516-2524	compared	_	_	_	_
12-31	2525-2527	to	_	_	_	_
12-32	2528-2530	an	person[139]	giv[139]	coref	13-30[152_139]
12-33	2531-2539	in-house	person[139]	giv[139]	_	_
12-34	2540-2545	ELISA	person[139]	giv[139]	_	_
12-35	2546-2547	,	_	_	_	_
12-36	2548-2553	using	_	_	_	_
12-37	2554-2559	crude	substance[140]	new[140]	_	_
12-38	2560-2567	extract	substance[140]	new[140]	_	_
12-39	2568-2570	of	substance[140]	new[140]	_	_
12-40	2571-2573	P.	substance[140]|animal|animal[142]	new[140]|giv|giv[142]	coref|coref	13-8|13-9[0_142]
12-41	2574-2584	falciparum	substance[140]|animal[142]	new[140]|giv[142]	_	_
12-42	2585-2588	3D7	substance[140]|animal[142]|abstract	new[140]|giv[142]|new	_	_
12-43	2589-2590	.	_	_	_	_

#Text=Thus , we showed that several other P. falciparum antigens are equally important for the serological diagnosis of malaria , as well as some recombinant antigens commonly used in commercial ELISA .
13-1	2591-2595	Thus	_	_	_	_
13-2	2596-2597	,	_	_	_	_
13-3	2598-2600	we	person	giv	_	_
13-4	2601-2607	showed	_	_	_	_
13-5	2608-2612	that	_	_	_	_
13-6	2613-2620	several	substance[147]	giv[147]	coref	13-24[151_147]
13-7	2621-2626	other	substance[147]	giv[147]	_	_
13-8	2627-2629	P.	animal|substance[147]	giv|giv[147]	_	_
13-9	2630-2640	falciparum	animal|substance[147]	giv|giv[147]	_	_
13-10	2641-2649	antigens	substance[147]	giv[147]	_	_
13-11	2650-2653	are	_	_	_	_
13-12	2654-2661	equally	_	_	_	_
13-13	2662-2671	important	_	_	_	_
13-14	2672-2675	for	_	_	_	_
13-15	2676-2679	the	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
13-16	2680-2691	serological	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
13-17	2692-2701	diagnosis	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
13-18	2702-2704	of	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
13-19	2705-2712	malaria	abstract[148]|abstract[149]|abstract	new[148]|giv[149]|giv	_	_
13-20	2713-2714	,	abstract[149]	giv[149]	_	_
13-21	2715-2717	as	abstract[149]	giv[149]	_	_
13-22	2718-2722	well	abstract[149]	giv[149]	_	_
13-23	2723-2725	as	abstract[149]	giv[149]	_	_
13-24	2726-2730	some	abstract[149]|substance[151]	giv[149]|giv[151]	_	_
13-25	2731-2742	recombinant	abstract[149]|substance[151]	giv[149]|giv[151]	_	_
13-26	2743-2751	antigens	abstract[149]|substance[151]	giv[149]|giv[151]	_	_
13-27	2752-2760	commonly	abstract[149]|substance[151]	giv[149]|giv[151]	_	_
13-28	2761-2765	used	abstract[149]|substance[151]	giv[149]|giv[151]	_	_
13-29	2766-2768	in	abstract[149]|substance[151]	giv[149]|giv[151]	_	_
13-30	2769-2779	commercial	abstract[149]|substance[151]|person[152]	giv[149]|giv[151]|giv[152]	_	_
13-31	2780-2785	ELISA	abstract[149]|substance[151]|person[152]	giv[149]|giv[151]|giv[152]	_	_
13-32	2786-2787	.	_	_	_	_
